Evofem Biosciences, Inc. announced it raised $25 Million in an initial filing from an offering of $25 Million

Company

Location

About

Evofem Biosciences, Inc., (OTCQB: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. In September 2020, Evofem launched Phexxi, the first and only hormone-free, on-demand, prescription birth control available in the U.S. that women use only when they have sex. In July 2024, Evofem acquired SOLOSEC, an FDA-approved single-dose oral antimicrobial agent for the treatment of two common sexual health infections: trichomoniasis and bacterial vaginosis.